시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 전정신경염 치료 시장 보고서(2025년)
Vestibular Neuronitis Treatment Global Market Report 2025
상품코드 : 1751165
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

전정신경염 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 6%의 성장률로 27억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 의료비 지출 증가, 신경 질환의 유병률 증가, 육종 발생률 증가, 귀 감염 증가, 균형 장애에 대한 인식 증가 등의 요인에 기인합니다. 이 기간 동안 예상되는 주요 동향으로는 인공지능(AI) 및 머신러닝(ML) 혁신, 전정 검사 기술의 발전, 약물전달 시스템의 새로운 개발, 원격 전정 치료를 위한 원격의료의 활용, 내이 평가를 위한 영상 기술의 향상 등이 있습니다.

바이러스 감염 사례의 증가는 전정신경염 치료 시장의 성장을 크게 촉진할 것으로 예상됩니다. 바이러스 감염은 숙주의 세포 내에 침입하여 복제하는 바이러스에 의해 발생하며, 전정신경에 영향을 미치는 것을 포함하여 다양한 증상과 합병증을 유발할 수 있습니다. 전 세계적으로 바이러스 감염증의 증가는 공기 중의 비말, 직접 접촉, 오염된 표면을 통해 바이러스의 확산을 촉진하는 전 세계 여행 및 도시화 등의 요인에 기인합니다. 전정신경염 치료는 주로 전정신경의 염증을 억제하고 어지럼증, 평형감각 장애 등의 증상을 완화시켜 내이에 영향을 미치는 바이러스 감염증의 관리에 중요한 역할을 합니다. 약물요법, 재활요법, 지지요법은 회복을 촉진하는 데 도움이 됩니다. 예를 들어, 2024년 10월 영국 보건안보국은 2023년 영국에서 인간면역결핍바이러스(HIV) 진단 건수가 6,008명으로 전년 대비 51% 증가했다고 보고했습니다. 바이러스 감염률이 증가함에 따라 전정신경염 관리와 같은 치료 수요도 증가하여 이 시장의 성장을 주도하고 있습니다.

전정신경염 치료 시장의 중요한 성장 촉진요인은 전 세계 의료 지출 증가입니다. 의료 서비스, 연구 및 치료에 대한 자금 지원의 증가는 특히 인구 고령화에 따라 증가하는 전문 치료에 대한 수요를 충족시키는 데 필수적입니다. 노인은 내이의 퇴화, 혈액순환 장애, 신경 기능 저하 등의 요인으로 인해 평형감각에 문제가 생기기 쉽고 전정신경염과 같은 전정 장애에 걸리기 쉽습니다. 의료비 지출의 증가는 의료 기술에 자금을 지원하고 더 나은 진단 및 치료법 연구를 지원하여 궁극적으로 치료 결과를 향상시킬 수 있습니다. 예를 들어, 미국 메디케어-메디케이드 서비스 센터(CMS)는 2024년 12월 국민의료비(NHE)가 2023년 7.5% 증가하여 GDP 성장률을 상회할 것이라고 보고했습니다. 이러한 의료비 지출 증가는 전정신경염 치료를 포함한 전문 치료에 대한 접근성 향상을 보장합니다. 지속적인 의료비 지출 증가로 인해 전정신경염 치료 시장도 계속 확대될 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Vestibular neuronitis treatment involves medical care and physical therapy aimed at managing and alleviating the symptoms of vestibular neuronitis, a condition caused by inflammation of the vestibular nerve. This inflammation leads to sudden episodes of vertigo, dizziness, and balance issues. The primary goal of treatment is to relieve these symptoms and support recovery. Treatment typically focuses on reducing inflammation of the vestibular nerve, managing symptoms, and promoting the brain's ability to compensate through vestibular rehabilitation exercises.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main treatment types in the vestibular neuronitis market include medication, physical therapy, surgery, and alternative therapy. Medication refers to drugs or substances used to diagnose, treat, prevent, or relieve the symptoms of the condition. These medications can be administered orally, intravenously, or intramuscularly. The condition affects various age groups, from children and adults to the elderly. Common symptoms include sudden vertigo, balance disturbances, nausea, vomiting, dizziness, and difficulty concentrating. The primary end users of these treatments are hospitals, clinics, and other healthcare providers.

The vestibular neuronitis treatment market research report is one of a series of new reports from The Business Research Company that provides vestibular neuronitis treatment market statistics, including vestibular neuronitis treatment industry global market size, regional shares, competitors with a vestibular neuronitis treatment market share, detailed vestibular neuronitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the vestibular neuronitis treatment industry. This vestibular neuronitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vestibular neuronitis treatment market size has grown strongly in recent years. It will grow from$2.08 billion in 2024 to $2.21 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to several factors, including increased awareness of vestibular disorders, a rising prevalence of chronic diseases, a higher occurrence of various vestibular disorders, an expanding geriatric population, and a growing prevalence of vestibular neuronitis.

The vestibular neuronitis treatment market size is expected to see strong growth in the next few years. It will grow to$2.79 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth during the forecast period can be attributed to factors such as increasing healthcare expenditure, a rising prevalence of neurological disorders, a higher incidence of sarcoma, an increase in ear infections, and growing awareness about balance disorders. Key trends expected during this period include innovations in artificial intelligence (AI) and machine learning (ML), advancements in vestibular testing technologies, new developments in drug delivery systems, the use of telemedicine for remote vestibular therapy, and improved imaging technologies for assessing the inner ear.

The rising cases of viral infections are expected to significantly propel the growth of the vestibular neuronitis treatment market. Viral infections, caused by viruses that invade and replicate within the host's cells, can lead to various symptoms and complications, including those affecting the vestibular nerve. The increasing global prevalence of viral infections is attributed to factors such as global travel and urbanization, which facilitate the spread of viruses through airborne droplets, direct contact, and contaminated surfaces. Vestibular neuronitis treatment plays a key role in managing viral infections that affect the inner ear, primarily by reducing inflammation of the vestibular nerve and alleviating symptoms such as dizziness and balance issues. Medications, rehabilitation therapy, and supportive care help speed recovery. For example, in October 2024, the UK Health Security Agency reported that human immunodeficiency virus (HIV) diagnoses in England had reached 6,008 in 2023, marking a 51% increase from the previous year. As the incidence of viral infections rises, the demand for treatments such as vestibular neuronitis management also increases, driving growth in this market.

An important driver of growth for the vestibular neuronitis treatment market is the rising healthcare expenditure globally. Increased funding in healthcare services, research, and treatments is vital to meet the growing demand for specialized care, particularly as the population ages. Older adults are more prone to developing balance issues, due to factors such as inner ear degeneration, poor blood circulation, and reduced nerve function, which makes them more susceptible to vestibular disorders such as vestibular neuronitis. Rising healthcare expenditures help fund medical technologies and support research into better diagnostic and therapeutic options, ultimately improving treatment outcomes. For instance, the Centers for Medicare & Medicaid Services (CMS) in the U.S. reported in December 2024 that national health expenditures (NHE) grew by 7.5% in 2023, surpassing GDP growth. This increase in healthcare spending ensures better access to specialized care, including treatments for vestibular neuronitis. With continued healthcare expenditure growth, the market for vestibular neuronitis treatment will also continue to expand.

The vestibular neuronitis treatment market is also experiencing significant innovation, with major companies focusing on advanced solutions such as vestibular modulators to improve treatment efficacy and speed recovery from vertigo. Vestibular modulators are therapeutic agents designed to regulate vestibular system activity, which helps improve balance, reduce vertigo, and enhance vestibular compensation in patients suffering from balance disorders. One notable advancement in this area is the development of intranasal therapies, which offer faster absorption and higher bioavailability. In June 2023, Altamira Therapeutics Ltd., a Switzerland-based biopharmaceutical company, received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its AM-125 (betahistine nasal spray) for treating acute vestibular syndrome (AVS). AM-125 works by enhancing histamine release, improving vestibular compensation, and increasing inner ear blood flow, which helps alleviate vertigo and balance issues. The intranasal delivery of this modulator ensures quicker symptom relief, revolutionizing the treatment landscape for dizziness and vestibular disorders. As such, innovative therapies such as these are expected to drive market growth further.

Major players in the vestibular neuronitis treatment market are Kaiser Permanente, Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Abbott Laboratories, Novartis AG, GSK plc, Bupa, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Recordati S.p.A., ANI Pharmaceuticals Inc., Prestige Consumer Healthcare Inc., Sun Pharmaceutical Industries Ltd., and LGM Pharma.

North America was the largest region in the vestibular neuronitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vestibular neuronitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vestibular neuronitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vestibular neuronitis treatment market consists of revenues earned by entities providing services such as diagnostic testing, lifestyle and dietary modifications, telemedicine, hospital and outpatient care, vestibular rehabilitation therapy and balance training exercises. The market value includes the value of related goods sold by the service provider or included within the service offering. The vestibular neuronitis market also includes sales of vestibular suppressants, anti-nausea medications, corticosteroids, vestibular rehabilitation devices and balance training equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vestibular Neuronitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vestibular neuronitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for vestibular neuronitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vestibular neuronitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Vestibular Neuronitis Treatment Market Characteristics

3. Vestibular Neuronitis Treatment Market Trends And Strategies

4. Vestibular Neuronitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Vestibular Neuronitis Treatment Growth Analysis And Strategic Analysis Framework

6. Vestibular Neuronitis Treatment Market Segmentation

7. Vestibular Neuronitis Treatment Market Regional And Country Analysis

8. Asia-Pacific Vestibular Neuronitis Treatment Market

9. China Vestibular Neuronitis Treatment Market

10. India Vestibular Neuronitis Treatment Market

11. Japan Vestibular Neuronitis Treatment Market

12. Australia Vestibular Neuronitis Treatment Market

13. Indonesia Vestibular Neuronitis Treatment Market

14. South Korea Vestibular Neuronitis Treatment Market

15. Western Europe Vestibular Neuronitis Treatment Market

16. UK Vestibular Neuronitis Treatment Market

17. Germany Vestibular Neuronitis Treatment Market

18. France Vestibular Neuronitis Treatment Market

19. Italy Vestibular Neuronitis Treatment Market

20. Spain Vestibular Neuronitis Treatment Market

21. Eastern Europe Vestibular Neuronitis Treatment Market

22. Russia Vestibular Neuronitis Treatment Market

23. North America Vestibular Neuronitis Treatment Market

24. USA Vestibular Neuronitis Treatment Market

25. Canada Vestibular Neuronitis Treatment Market

26. South America Vestibular Neuronitis Treatment Market

27. Brazil Vestibular Neuronitis Treatment Market

28. Middle East Vestibular Neuronitis Treatment Market

29. Africa Vestibular Neuronitis Treatment Market

30. Vestibular Neuronitis Treatment Market Competitive Landscape And Company Profiles

31. Vestibular Neuronitis Treatment Market Other Major And Innovative Companies

32. Global Vestibular Neuronitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vestibular Neuronitis Treatment Market

34. Recent Developments In The Vestibular Neuronitis Treatment Market

35. Vestibular Neuronitis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기